Q-omics provides the consensus-scored DLX3 profile across patient tissues and cancer cell-line models. DLX3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, DLX3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DLX3 RNA expression shows 13,265 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, KIRC, and TGCT as cancer lineages where DLX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLX3 survival associations across molecular data types. DLX3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLX3 RNA expression–survival associations across cancer types. High DLX3 expression shows unfavorable associations in COAD, PAAD, UCS, SKCM and DLBC, but favorable associations in LUAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for DLX3 RNA expression.
This table summarizes DLX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DLX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLX3 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in LUSC, UCEC and BRCA. The KIRC box plot shows higher DLX3 RNA expression in normal versus tumor tissue (log2 FC = −0.892, t-test p < 0.001).
This table shows molecular features associated with DLX3 in patient tissues and cancer cell lines. In patient samples, DLX3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DLX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
